Tissue factor in the antiphospholipid syndrome

Lupus

Volumn 17, Issue 10, 2008, Pages 952-958

  Kinev, A V ^a   Roubey, Robert A S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiphospholipid syndrome; Thrombosis; Tissue factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTICOAGULANT AGENT; ATORVASTATIN; AUTOANTIBODY; BLOOD CLOTTING FACTOR 7A; CELL SURFACE RECEPTOR; COMPLEMENT; CURCUMIN; DEFIBROTIDE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUINDOSTATIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTOXIFYLLINE; PHOSPHOLIPID ANTIBODY; PLACEBO; SIMVASTATIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TURMERIC;

ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BLOOD CELL; BLOOD CLOTTING; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY DISORDER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; RED WINE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; VASCULAR ENDOTHELIUM; ANTIGEN ANTIBODY REACTION; METABOLISM; PHYSIOLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGEN-ANTIBODY REACTIONS; ANTIPHOSPHOLIPID SYNDROME; GENE EXPRESSION REGULATION; HUMANS; SIGNAL TRANSDUCTION; THROMBOPLASTIN;

EID: 59649088107     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308096662     Document Type: Review

References (94)

1. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433-2439.
2. Monroe DM Key NS. The tissue factor-factor VIIa complex: Procoagulant activity, regulation, and multitasking. J Thrombi Haemostat 2007; 5: 1097-1105.
3. Roubey RA. Antiphospholipid syndrome: Antibodies and antigens. Cur Open Heaton 2000; 7: 316-320.
4. Harris EN Chan JKH. Asher son, RA, Abler, VR, Gravari, AE, Hughes, GR. Thrombosis, recurrent fatal loss, thrombocytopenia: Predictive value of IgG anticardiolipin antibodies. Arch Intern Med 1986; 146: 2153-2156.
5. Ginsburg KS Lang MH Newcomer L. et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
6. Blank M Cohen J Tower V Sheffield Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiologic antibodies. Proc Natal Aced Sic U S A 1991; 88: 3069-3073.
7. Pierangeli SS Barker JH Strikeover D. et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thrombi Haemostat 1994; 71: 670-674.
8. Roadway-Bright EL Incan M Isenberg DA. Animal models of the antiphospholipid syndrome. Rheumatology (Oxford) 1999; 38: 591-601.
9. Del Papa N Guidable L Salad A. et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40: 551-561.
10. Simonton R LaSalle JM Lo SK. et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clint Invest 1995; 96: 2211-2219.
11. Zhou H Walberg AS Roubey RAS. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-2358.
12. Spicer EK Horton R Bloom L. Isolation of coda clones coding for human tissue factor: Primary structure of the protein and coda. Proc Natal Aced Sic U S A 1987; 84: 5148-5152.
13. Mack man, N. Role of tissue factor in haemostasis and thrombosis. Blood Cells Mol Dies 2006; 36: 104-107.
14. Humber J Wohlgensinger C Roux S. et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thrombi Haemostat 2003; 1: 889-895.
15. Mack man N, Tilley, RE, Key, NS. Role of the extrinsic pathway of blood coagulation in haemostasis and thrombosis. Arteriosclerosis Thrombi Vacs Boil 2007; 27: 1687-1693.
16. Conking PR Greenberg CS Weinberg JB. Tumour necrosis factor induces tissue factor-like activity in human leukaemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-133.
17. Tenino T Bottling J Oberg F Nilsson K Siobhan A. Tissue factor expression in human monocytic cell lines. Thrombi Rees 1997; 88: 215-228.
18. Muhlfelder TW Teodorescu V Rand J Roman A Kismets J. Human athermanous plaque extracts induce tissue factor activity (Tea) in monocytes and also express constitutive Tea. Thrombi Haemostat 1999; 81: 146-150.
19. Kauri A Houston DS. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis. Blood 2000; 96: 966-972.
20. Edwards RL Reckless FR Crosland M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clint Med 1981; 98: 917-928.
21. Rio LV Pendurthi UR. Tissue factor-factor VIIa signalling. Arteriosclerosis Thrombi Vacs Boil 2005; 25: 47-56.
22. Belting M Ashamed J Ruff W. Signalling of the tissue factor coagulation pathway in angiogenesis and cancer. Arteriosclerosis Thrombi Vacs Boil 2005; 25: 1545-1550.
23. Paulsen LK Jacobsen N Sorensen BB. et al. Signal transduction via the mutagen-activated protein kinas pathway induced by binding of coagulation factor VIIa to tissue factor. J Boil Chem 1998; 273: 6228-6232.
24. Mack man, N. Role of tissue factor in haemostasis, thrombosis, and vascular development. Arteriosclerosis Thrombi Vacs Boil 2004; 24: 1015-1022.
25. Cuadrado MJ López-Pedrera C Khamashta MA. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-841.
26. Dobado-Berrios PM Lopez-Pedrera C Velasco F Aguirre MA Torres A Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thrombi Haemostat 1999; 82: 1578-1582.
27. Reverter JC Tassies D Font J. et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arteriosclerosis Thrombi Vacs Boil 1996; 16: 1319-1326
28. Nojima J Masuda Y Iwatani Y. et al. Tissue factor expression on monocytes induced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Rees Commun 2008; 365: 195-200.
29. Kornberg A Blank M Kaufman S Sheffield Y. Induction of tissue factor-like activity in monocytes by anti-cardiologic antibodies. J Immunol 1994; 153: 1328-1332.
30. Amengual O Atsumi T Khamashta MA Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombi Haemostat 1998; 79: 276-281.
31. Reverter JC Tassies D Font J. et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 1420-1427.
32. Vega-Ostertag M Casper K Swerlick R Ferrara D Harris EN Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-1554.
33. Lopez-Pedrera C Buendia P Barbarroja N Siendones E Velasco F Cuadrado MJ. Antiphospholipid-mediated thrombosis: Interplay between anticardiolipin antibodies and vascular cells. Clint Appl Thrombi Hemost 2006; 12: 41-45.
34. Kornberg A; Renaudineau Y Blank M Youinou P Sheffield Y. Anti-beta2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2000; 2: 27-31.
35. Vega-Ostertag ME Ferrara DE Romay-Penabad Z. et al. Role of p38 mutagen-activated protein kinas in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thrombi Haemostat 2007; 5: 1828-1834.
36. Yan SF. Mack man, N, Kisiel, W, Stern, DM, Pinsky, DJ. Hypoxia/ hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arteriosclerosis Thrombi Vacs Boil 1999; 19: 2029-2035.
37. Nishibe T Parry G Ishida A. et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: Evidence for Erk-1/2 activation. Blood 2001; 97: 692-699.
38. Brand K Fowler BJ Edgington TS. Mack man, N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Boil 1991; 11: 4732-4738.
39. Reddy KV Bhattacharjee G Schabbauer G. et al. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability. J Leukoc Boil 2004; 76: 145-151.
40. Gregory SA Morrissey JH Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Boil 1989; 9: 2752-2755.
41. Monroe DM Hoffman M Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagul Fibrinolysis 1996; 7: 459-464.
42. Chen VM Ashamed J Versteeg HH Berndt MC Ruff W Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 12020-12028.
43. Ashamed J Versteeg HH Kerver M. et al. Disulfide isomerization switches tissue factor from coagulation to cell signalling. Proc Natal Aced Sic U S A 2006; 103: 13932-13937.
44. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Boil Chem 2000; 275: 15541-15548.
45. Zhang J McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-{beta}2-Glycoprotein I antibodies. Blood 2005; 105: 1964-1969.
46. May P Woldt E Matz RL Boucher P. The LDL receptor-related protein (LRP) family: An old family of proteins with new physiological functions. Ann Med 2007; 39: 219-228.
47. Pennings MT. van Lummel M., Derksen, RH, et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thrombi Haemostat 2006; 4: 1680-1690.
48. Moestrup SK Schousboe I Jacobsen C Leheste JR Christensen EI Willnow TE. Beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clint Invest 1998; 102: 902-909.
49. Lutters BC Derksen RH Tekelenburg WL Lenting PJ Arnout J de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Boil Chem 2003; 278: 33831-33838.
50. Pennings MT Derksen RH. van Lummel M. et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: Glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thrombi Haemostat 2007; 5: 369-377.
51. Urbanus RT Pennings MT Derksen RH De Groot PG. Platelet activation by dimeric beta(2)-glycoprotein I requires signalling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2008; 6: 1405-1412.
52. Maiti SN Balasubramanian K Ramoth JA Schroit AJ. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Boil Chem 2008; 283: 3761-3766.
53. Raschi E Testoni C Bosisio D. et al. Role of the MyD88 transduction signalling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
54. Pierangeli SS Vega-Ostertag ME Raschi E. et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dies 2007; 66: 1327-1333.
55. Bohgaki M Atsumi T Yamashita Y. et al. The p38 mutagen-activated protein kinas (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641.
56. Yasuda S Bohgaki M Atsumi T Koike T. Pathogenesis of antiphospholipid antibodies: Impairment of fibrinolysis and monocyte activation via the p38 mutagen-activated protein kinas pathway. Immunobiology 2005; 210: 775-780.
57. Oda K Kitano H. A comprehensive map of the toll-like receptor signalling network. Mol Syst Boil 2006; 2: 2006.
58. Aronovich R Gurwitz D Kloog Y Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005; 210: 781-788.
59. Lopez-Pedrera C Buendia P Cuadrado MJ. et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mutagen-activated protein kinas pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-311.
60. Kinev AV Romay-Penabad Z Liu X Pierangeli SS Roubey RAS. The transcription factor Egr-1 plays a critical role in antiphospholipid antibody-mediated thrombosis. J Thrombi Haemostat 2007; 5(Suppl. 2): O-S-012 [abstract]
61. Khachigian LM. Early growth response-1 in cardiovascular pathobiology. Circ Rees 2006; 98: 186-191.
62. Yan SF Zou YS Gao Y. et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natal Aced Sic U S A 1998; 95: 8298-8303.
63. Mack man N. Regulation of the tissue factor gene. Thrombi Haemostat 1997; 78: 747-754.
64. Salmon JE Girardi G. The role of complement in the antiphospholipid syndrome. Cur Dir Autoimmun 2004; 7: 133-148.
65. Girardi G Redecha P Salmon JE. Heparin prevents antiphospholipid antibody-induced fatal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
66. Holers VM Girardi G Mo L. et al. Complement C3 activation is required for antiphospholipid antibody-induced fatal loss. J Exp Med 2002; 195: 211-220.
67. Pierangeli SS Girardi G Vega-Ostertag M Liu X Espinola RG Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-2124.
68. Ritis K Doumas M Mastellos D. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177: 4794-4802.
69. Redecha P Tilley R Tencati M. et al. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fatal injury. Blood 2007; 110: 2423-2431.
70. Taylor FB Chang AC Peer G Li A Ezban M Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998; 91: 1609-1615.
71. Taylor FB Chang A Ruff W. et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
72. Carr C Bild GS Chang AC. et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-137.
73. Undas A Brummel-Ziedins KE Mann KG. Statins and blood coagulation. Arteriosclerosis Thrombi Vacs Boil 2005; 25: 287-294.
74. Ferro D Basili S Alessandri C Cara D Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149: 111-116.
75. Eto M Kozai T Cosentino F Joch H Luscher TF. Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759.
76. Hilgendorff A Muth H Parviz B. et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clint Pharmacol Ther 2003; 41: 397-401.
77. Steiner S Speidl WS Pleiner J. et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-1846.
78. Meroni PL Raschi E Testoni C. et al.Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-2878.
79. Ferrara DE Swerlick R Casper K. et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thrombi Haemostat 2004; 2: 1558-1563.
80. Dunoyer-Geindre S Dimitrova Y Fish RJ. et al. Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thrombi Haemostat 2005; 93: 339-345.
81. Ferrara DE Liu X Espinola RG. et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279.
82. Deguchi H Takeya H Wada H. et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997; 90: 2345-2356.
83. Broussas M Cornillet-Lefebvre P Potron G Nguyen P. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: Involvement of the A3 adenosine receptor. Thrombi Haemostat 2002; 88: 123-130.
84. Ho VT Linden E Revta C Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Review and update on the use of defibrotide. Semin Thrombi Hemost 2007; 33: 373-388.
85. Falanga A Vignoli A Marchetti M Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukaemia 2003; 17: 1636-1642.
86. Asher son R.A. Cervera R. Piette J.C. et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207.
87. Burcoglu-O'Ral A Erkan D. Asher son, R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002; 29: 2006-2011.
88. de Prost D. Pentoxifylline: A potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J Cardiovasc Pharmacol 1995; 25(Suppl. 2): S114-S118.
89. Susen S Hazzan M Labalette M. et al. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications. Thrombi Haemostat 2000; 84: 764-769.
90. Napoleone E Di Santo A Camera M Tremoli E Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Rees 2000; 86: 139-143.
91. Wang J Mahmud SA Bitterman PB Huo Y Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Boil Chem 2007; 282: 28408-28418.
92. Bierhaus A Zhang Y Quehenberger P. et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thrombi Haemostat 1997; 77: 772-782.
93. Pendurthi UR Williams JT Rio LV. Inhibition of tissue factor gene activation in cultured endothelial cells by cur cumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arteriosclerosis Thrombi Vacs Boil 1997; 17: 3406-3413.
94. Casani L Segales E Vilahur G. Bayes de LA Badimon L. Moderate daily intake of red wine inhibits mural thrombosis and monocyte tissue factor expression in an experimental porcine model. Circulation 2004; 110: 460-465.